IS7017A - Tengd pýrazínon, pýridín og pýrimídín sem bindlarlosunarþátts kortíkótrópíns - Google Patents

Tengd pýrazínon, pýridín og pýrimídín sem bindlarlosunarþátts kortíkótrópíns

Info

Publication number: IS7017A
Authority: IS; Iceland
Prior art keywords: pyrazinone; corticotropin; pyrimidine; pyridine; binding agent
Prior art date: 2001-05-14

Application number

IS7017A

Other languages

English (en)

Inventor

G. Arvanitis Argyrios

J. Gilligan Paul

A. Hartz Richard

Original Assignee

Bristol-Myers Squibb Pharma Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-14

Filing date

2003-11-07

Publication date

2003-11-07

2003-11-07 Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company

2003-11-07 Publication of IS7017A publication Critical patent/IS7017A/is

Links

JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 title 1
102400000739 Corticotropin Human genes 0.000 title 1
101800000414 Corticotropin Proteins 0.000 title 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
239000011230 binding agent Substances 0.000 title 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 title 1
229960000258 corticotropin Drugs 0.000 title 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Immunology (AREA)
Virology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Obesity (AREA)
Dermatology (AREA)

IS7017A 2001-05-14 2003-11-07 Tengd pýrazínon, pýridín og pýrimídín sem bindlarlosunarþátts kortíkótrópíns IS7017A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29070601P	2001-05-14	2001-05-14
PCT/US2002/015493 WO2002092090A1 (en)	2001-05-14	2002-05-14	Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands

Publications (1)

Publication Number	Publication Date
IS7017A true IS7017A (is)	2003-11-07

Family

ID=23117196

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7017A IS7017A (is)	2001-05-14	2003-11-07	Tengd pýrazínon, pýridín og pýrimídín sem bindlarlosunarþátts kortíkótrópíns

Country Status (22)

Country	Link
US (2)	US7205306B2 (is)
EP (1)	EP1392309B1 (is)
JP (1)	JP2004533447A (is)
KR (1)	KR20030094410A (is)
CN (1)	CN1527710A (is)
BG (1)	BG108425A (is)
BR (1)	BR0209575A (is)
CA (1)	CA2446980A1 (is)
CZ (1)	CZ20033053A3 (is)
DE (1)	DE60217669D1 (is)
EE (1)	EE200300546A (is)
HU (1)	HUP0304048A2 (is)
IL (1)	IL158669A0 (is)
IS (1)	IS7017A (is)
MX (1)	MXPA03010324A (is)
NO (1)	NO20035055D0 (is)
PL (1)	PL366577A1 (is)
RU (1)	RU2003135424A (is)
SK (1)	SK13752003A3 (is)
WO (1)	WO2002092090A1 (is)
YU (1)	YU90503A (is)
ZA (1)	ZA200308729B (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2525195A1 (en) *	2003-05-09	2004-11-18	Pharmacia & Upjohn Company Llc	Pyrazinones as crf1 receptor antagonists for the treatment of cns disorders
AU2004295050A1 (en)	2003-11-24	2005-06-16	F.Hoffmann-La Roche Ag	Pyrazolyl and imidazolyl pyrimidines
KR20070034049A (ko)	2004-06-09	2007-03-27	글락소 그룹 리미티드	피롤로피리딘 유도체
GB0420722D0 (en) *	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
GT200500284A (es) *	2004-10-15	2006-03-27	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
US20060161001A1 (en) *	2004-12-20	2006-07-20	Amgen Inc.	Substituted heterocyclic compounds and methods of use
GT200600005A (es) *	2005-01-12	2006-08-16		Un derivado de 2-(aminocarbonilo ciclico)-indolina y una composicion farmaceutica que lo contiene
TW200640881A (en) *	2005-02-15	2006-12-01	Du Pont	Fungicidal pyrazine derivatives
AR059898A1 (es)	2006-03-15	2008-05-07	Janssen Pharmaceutica Nv	Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
JP2009541321A (ja) *	2006-06-21	2009-11-26	イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー	細胞増殖阻害剤としてのピラジノン
NZ578096A (en) *	2007-01-10	2011-11-25	Albany Molecular Res Inc	5-pyridinone substituted indazoles
WO2008107398A2 (en) *	2007-03-02	2008-09-12	Basf Se	Pyrazine compounds
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CN101861311A (zh) *	2007-07-21	2010-10-13	阿尔巴尼分子研究公司	5-吡啶酮取代的吲唑
PL2200985T3 (pl)	2007-09-14	2011-12-30	Ortho Mcneil Janssen Pharmaceuticals Inc	1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
CN101801930B (zh)	2007-09-14	2013-01-30	奥梅-杨森制药有限公司	1,3-二取代的-4-苯基-1h-吡啶-2-酮
SI2203439T1 (sl)	2007-09-14	2011-05-31	Ortho Mcneil Janssen Pharm	1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
CN101861316B (zh)	2007-11-14	2013-08-21	奥梅-杨森制药有限公司	咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
NZ589555A (en)	2008-04-29	2012-08-31	Merck Patent Gmbh	Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
JP2011529899A (ja) *	2008-07-31	2011-12-15	ブリストル−マイヤーズスクイブカンパニー	副腎皮質刺激ホルモン放出因子受容体活性のモジュレーターとしての置換カルバメート誘導体
EP2344470B1 (en)	2008-09-02	2013-11-06	Janssen Pharmaceuticals, Inc.	3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en)	2008-10-16	2010-04-22	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja)	2008-11-28	2015-03-25	ジャンセンファーマシューティカルズ，インコーポレイテッド．	代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
BRPI1010831A2 (pt)	2009-05-12	2016-04-05	Addex Pharmaceuticals Sa	derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh)	2009-05-12	2015-04-29	杨森制药有限公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
ES2536433T3 (es)	2010-11-08	2015-05-25	Janssen Pharmaceuticals, Inc.	Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9271967B2 (en)	2010-11-08	2016-03-01	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
AU2011328203B2 (en)	2010-11-08	2015-03-19	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CN102786512A (zh) *	2012-05-31	2012-11-21	中国人民解放军军事医学科学院毒物药物研究所	N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me)	2014-01-21	2020-04-20	Janssen Pharmaceutica Nv	Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
MX386697B (es)	2014-01-21	2025-03-19	Janssen Pharmaceutica Nv	Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
CN119613318B (zh) *	2024-11-29	2026-04-14	滁州市庆云医药有限公司	一种西洛多辛中间体及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0008864A1 (en) *	1978-08-15	1980-03-19	FISONS plc	Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
IE63502B1 (en) *	1989-04-21	1995-05-03	Zeneca Ltd	Aminopyrimidine derivatives useful for treating cardiovascular disorders
DE4029648A1 (de) *	1990-09-19	1992-03-26	Hoechst Ag	4-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
US5395817A (en) *	1992-01-22	1995-03-07	Imperial Chemical Industries Plc	N-arylindoles and their use as herbicides
FR2694004B1 (fr) *	1992-07-21	1994-08-26	Adir	Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
KR19990067704A (ko)	1992-12-17	1999-08-25	디. 제이. 우드, 스피겔 알렌 제이	부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
WO1995010506A1 (en)	1993-10-12	1995-04-20	The Du Pont Merck Pharmaceutical Company	1n-alkyl-n-arylpyrimidinamines and derivatives thereof
JP2000507552A (ja)	1996-03-26	2000-06-20	デュポンファーマシューティカルズカンパニー	アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体
US6107300A (en)	1996-03-27	2000-08-22	Dupont Pharmaceuticals	Arylamino fused pyrimidines
TW440563B (en) *	1996-05-23	2001-06-16	Hoffmann La Roche	Aryl pyrimidine derivatives and a pharmaceutical composition thereof
AU3064397A (en)	1996-05-24	1997-12-09	Dow Chemical Company, The	Process for preparing aliphatic ester compounds and alkanols
HU229024B1 (en)	1996-07-24	2013-07-29	Bristol Myers Squibb Pharma Co	Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
US6159980A (en)	1996-09-16	2000-12-12	Dupont Pharmaceuticals Company	Pyrazinones and triazinones and their derivatives thereof
PL337888A1 (en)	1997-07-03	2000-09-11	Du Pont Pharm Co	Imidazoprimidines and imidazopyridines for use in treating neurological disorders
AU8181098A (en)	1997-07-03	1999-01-25	Du Pont Pharmaceuticals Company	Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
US6245769B1 (en)	1997-09-02	2001-06-12	Dupont Pharmaceuticals Company	Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
JP2002510695A (ja)	1998-04-03	2002-04-09	デュポンファーマシューティカルズカンパニー	副腎皮質刺激ホルモン放出因子（ＣＲＦ）拮抗剤としてのチアゾロ［４，５−ｄ］ピリミジンおよびピリジン
US6124463A (en)	1998-07-02	2000-09-26	Dupont Pharmaceuticals	Benzimidazoles as corticotropin release factor antagonists
EP1105394A1 (en)	1998-08-21	2001-06-13	Du Pont Pharmaceuticals Company	ISOXAZOLO 4,5-d]PYRIMIDINES AS CRF ANTAGONISTS

2002
- 2002-05-14 CN CNA028140907A patent/CN1527710A/zh active Pending
- 2002-05-14 JP JP2002589007A patent/JP2004533447A/ja active Pending
- 2002-05-14 EP EP02729225A patent/EP1392309B1/en not_active Expired - Lifetime
- 2002-05-14 HU HU0304048A patent/HUP0304048A2/hu unknown
- 2002-05-14 CZ CZ20033053A patent/CZ20033053A3/cs unknown
- 2002-05-14 MX MXPA03010324A patent/MXPA03010324A/es unknown
- 2002-05-14 DE DE60217669T patent/DE60217669D1/de not_active Expired - Lifetime
- 2002-05-14 RU RU2003135424/04A patent/RU2003135424A/ru not_active Application Discontinuation
- 2002-05-14 KR KR10-2003-7014755A patent/KR20030094410A/ko not_active Withdrawn
- 2002-05-14 EE EEP200300546A patent/EE200300546A/xx unknown
- 2002-05-14 BR BR0209575-0A patent/BR0209575A/pt not_active IP Right Cessation
- 2002-05-14 US US10/145,440 patent/US7205306B2/en not_active Expired - Lifetime
- 2002-05-14 IL IL15866902A patent/IL158669A0/xx unknown
- 2002-05-14 CA CA002446980A patent/CA2446980A1/en not_active Abandoned
- 2002-05-14 WO PCT/US2002/015493 patent/WO2002092090A1/en not_active Ceased
- 2002-05-14 PL PL02366577A patent/PL366577A1/xx unknown
- 2002-05-14 YU YU90503A patent/YU90503A/sh unknown
- 2002-05-14 SK SK1375-2003A patent/SK13752003A3/sk unknown
2003
- 2003-11-07 IS IS7017A patent/IS7017A/is unknown
- 2003-11-10 ZA ZA200308729A patent/ZA200308729B/en unknown
- 2003-11-13 NO NO20035055A patent/NO20035055D0/no not_active Application Discontinuation
- 2003-12-08 BG BG108425A patent/BG108425A/xx unknown
2007
- 2007-02-14 US US11/675,012 patent/US7319100B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CZ20033053A3 (en)	2004-05-12
IL158669A0 (en)	2004-05-12
EE200300546A (et)	2004-04-15
EP1392309A4 (en)	2006-01-18
US7205306B2 (en)	2007-04-17
ZA200308729B (en)	2005-02-10
US20070155740A1 (en)	2007-07-05
PL366577A1 (en)	2005-02-07
YU90503A (sh)	2006-03-03
JP2004533447A (ja)	2004-11-04
BG108425A (en)	2004-12-30
SK13752003A3 (en)	2004-11-03
NO20035055D0 (no)	2003-11-13
BR0209575A (pt)	2004-04-20
US7319100B2 (en)	2008-01-15
HK1059220A1 (en)	2004-06-25
CA2446980A1 (en)	2002-11-21
EP1392309A1 (en)	2004-03-03
WO2002092090A1 (en)	2002-11-21
RU2003135424A (ru)	2005-05-20
HUP0304048A2 (hu)	2004-04-28
DE60217669D1 (de)	2007-03-08
EP1392309B1 (en)	2007-01-17
MXPA03010324A (es)	2004-02-17
CN1527710A (zh)	2004-09-08
US20030171380A1 (en)	2003-09-11
KR20030094410A (ko)	2003-12-11

Publication	Publication Date	Title
IS7017A (is)	2003-11-07	Tengd pýrazínon, pýridín og pýrimídín sem bindlarlosunarþátts kortíkótrópíns
PL370480A1 (en)	2005-05-30	Aminopyrimidines and pyridines
NO20024308D0 (no)	2002-09-09	Arylsubstituerte pyridiner, pyrimidiner og triaziner og deres anvendelse
IL176805A0 (en)	2006-10-31	Novel pyridine derivative and pyrimidine derivative (1)
NO20052555D0 (no)	2005-05-26	5-substituerte pyrazin- eller pyridin-glucokinase-aktivatorer.
PL375395A1 (en)	2005-11-28	4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines
IL165046A0 (en)	2005-12-18	Pyrimidinone compounds, compositions and methods
IS7749A (is)	2005-03-17	Pýrimídínafleiður og notkun þeirra sem CB2 beina
DK1455785T3 (da)	2009-06-08	Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
ZA200709572B (en)	2009-05-27	Novel pyridine derivative and pyrimidine derivative (3)
EP1831170A4 (en)	2009-10-14	SUBSTITUTED AMINOPYRIDINES AND THEIR USE
NO20042676L (no)	2004-08-24	3-beta-d-ribofuranolsyltiazolo[4,5-d]pyrimidinnukleosider og anvendelser derav
IL176199A0 (en)	2006-10-05	Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors
IL176060A0 (en)	2006-10-05	6-substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerse inhibitors
IL175756A0 (en)	2006-09-05	7-phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly (adp-ribose) polymerase inhibitors
NO20055568D0 (no)	2005-11-24	Substituerte 1,4-diazepiner og anvendelser derav
AU2003301066A8 (en)	2004-09-06	Al2o3-la2o3-y2o3-mgo ceramics, and methods of making the same
GB2393055B (en)	2006-08-30	Transconductance amplifiers
AU2003243657A8 (en)	2004-01-19	Amino-bicyclic pyrazinones and pyridinones
IL159540A0 (en)	2004-06-01	Heterocyclic compounds as selective bacterial dhfr inhibitors and the uses thereof
MXPA03007022A (es)	2003-11-18	Sales de avermectinas sustituidas en la posicion 4" y que tienen propiedades plaguicidas.
IL174497A0 (en)	2006-08-01	Pyridine derivatives and use thereof as urotensin ii antagonists
AU2003274905A8 (en)	2004-06-23	Recombinant double-stranded rna phage, and use of the same
AU2003264757A8 (en)	2004-04-30	Transconductance amplifiers
AU2003265175A8 (en)	2004-03-29	Pyridazinone and pyridone derivatives as adenosine antagonists